Showing 6281-6290 of 8699 results for "".
- FDA Approves Galderma's Aklief (trifarotene) Cream for Acnehttps://practicaldermatology.com/news/fda-approves-galdermas-aklief-trifarotene-cream-for-acne/2460164/The FDA has approved Galderma's Aklief (trifarotene) Cream, 0.005% for the topical treatment of acne. Aklief Cream is the only topical retinoid that selectively targets retinoic acid receptor (RAR) gamma, the most common RAR found in the skin. Trifarotene is the first new retinoid molecule to
- La Roche-Posay Foundation Opens Call for Abstractshttps://practicaldermatology.com/news/la-roche-posay-foundation-opens-call-for-abstracts/2460163/The La Roche-Posay North American Foundation has opened a call for scientific abstracts. The La Roche-Posay North American Foundation was established in 2005 to support outstanding candidates with promising projects in the field of clinical, biological or pharmacological research linked to
- Electric Tech May Help Reverse Baldnesshttps://practicaldermatology.com/news/electric-tech-may-help-reverse-baldness/2460156/Reversing baldness could someday be as easy as wearing a hat, thanks to a noninvasive, low-cost hair-growth-stimulating technology developed by engineers at the University of Wisconsin–Madison. Xudong Wang, a professor of materials science and engineering at UW–Madison. and
- Pediatric Dermatologist Who Co-Founded Camp for Children Recognized for Carehttps://practicaldermatology.com/news/pediatric-dermatologist-who-co-founded-camp-for-children-recognized-for-care/2460153/The American Academy of Dermatology honored dermatologist Karen Wiss, MD, FAAD, as a Patient Care Hero for her role in treating a patient with recessive dystrophic epidermolysis bullosa (RDEB). To support pediatric patients with isolating conditions like RDEB, Dr. Wiss, a derm
- Positive Results for Aclaris Therapeutics’ A-101 45% Topical Solution in Pivotal Phase 3 Trial for the Treatment of Wartshttps://practicaldermatology.com/news/positive-results-for-aclaris-therapeutics-a-101-45-topical-solution-in-pivotal-phase-3-trial-for-the-treatment-of-warts/2460151/Aclaris Therapeutics, Inc., shared positive results from its Phase 3 clinical trial, THWART-2 (WART-302), of A-101 45% Topical Solution, an investigational new drug for the treatment of common warts (verruca vulgaris). A-101 45% Topical Solution met the
- Study: Long-Term Use of Brodalumab Is Safe, Effectivehttps://practicaldermatology.com/news/study-long-term-use-of-brodalumab-is-safe-effective/2460150/Long-term use of brodalumab (SILIQ) improved skin clearance and quality of life in patients with moderate-to-severe psoriasis, according to a new study in the American Journal of Clinical Dermatology. Ov
- With Fibrocell Acquisition, Castle Creek Expands Late-Stage EB Pipelinehttps://practicaldermatology.com/news/with-fibrocell-acquisition-castle-creek-expands-late-stage-eb-pipeline/2460149/Castle Creek Pharmaceutical Holdings, Inc. acquired Fibrocell Science, Inc., a cell and gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases. With the resources of CCP Holdings’ subsidiary,
- Increased Adherence, Symptom Improvement Seen When Psoriasis Patients Switch to IL-17 Blockershttps://practicaldermatology.com/news/increased-adherence-symptom-improvement-seen-when-psoriasis-patients-switch-to-il-17-blockers/2460147/New data points to increased adherence and improvement in symptoms for psoriasis patients who switch to interleukin-17 inhibitors. The study, which was conducted with Walgreens, a parent company of AllianceRx Walgreens Prime, was presented at the National Association of Specialty Pharma
- SENTÉ Partners with Scientis to Introduce Cysperahttps://practicaldermatology.com/news/sente-partners-with-scientis-to-introduce-cyspera/2460146/SENTÉ is partnering with Scientis, a Swiss dermatology company dedicated to developing novel dermo-cosmetic solutions to address skin pigmentation concerns, to introduce Cyspera®. Cyspera, a physician exclusive skincare product, is a novel intensive
- Melanoma Breakthrough: Researchers Discover Why Some Patients Respond to Immunotherapyhttps://practicaldermatology.com/news/melanoma-breakthrough-researchers-discover-why-some-patients-respond-to-immunotherapy-yet-others-dont/2460143/Israeli researchers now know why 60 percent of patients with metastatic melanoma do not respond to immunotherapy. After examining tumors of 116 patients using proteomics, the researchers found the non-responding patients tended to have lower fatty acid metabolism, meaning that their enz